Patritumab deruxtecan is a monoclonal antibody conjugated commercialized by , with a leading Phase III program in Non-Small Cell Lung Cancer. According to Globaldata, it is involved in 17 clinical trials, of which 2 were completed, 12 are ongoing, 2 are planned, and 1 was terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Patritumab deruxtecanÂ’s valuation in its risk-adjusted NPV model (rNPV). .
The revenue for Patritumab deruxtecan is expected to reach an annual total of $110 mn by 2036 in the US based off GlobalDataÂ’s Expiry Model. The drugÂ’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drugÂ’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Patritumab deruxtecan Overview
It was under development for the treatment of metastatic colorectal cancer, colon cancer, rectal adenocarcinoma, bladder cancer and skin cancer.
Daiichi Sankyo Overview
is a holding company, which carries out the research, development, manufacture, and marketing of pharmaceutical products. The company offers a wide range of prescription drugs, over the counter (OTC) drugs, vaccines, and others. Its portfolio encompasses medicines for cardiovascular, neurological, nephrological, diabetic, metabolic, and infectious diseases, and various types of cancers. Besides cancer, the companyÂ’s other research areas include rare diseases and immune disorders. sells its products through its group companies and an extensive network of medical representatives. It has operations in North America, South and Central America, Europe, and Asia. is headquartered in Tokyo, Japan.
The company reported revenues of (Yen) JPY1,601,688 million for the fiscal year ended March 2024 (FY2024), an increase of 25.3% over FY2023. In FY2024, the companyÂ’s operating margin was 13.6%, compared to an operating margin of 9.3% in FY2023. In FY2024, the company recorded a net margin of 12.5%, compared to a net margin of 8.5% in FY2023.
For a complete picture of Patritumab deruxtecanÂ’s valuation,
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.